Zolymbus

(Bimatoprost)

ApprovedSmall molecule

Zolymbus is a small molecule that works as a Prostanoid FP Receptor Agonist.[2] It is being used across 18 indications, with its most advanced program in Approved.[1]

Zolymbus is one of 358 small molecule programs targeting Alopecia. It is currently in Approved.

Indications

Total Trials

Active Trials

357

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

AlopeciaActive, not recruiting

GlaucomaActive, not recruiting

Hypotrichosis SimplexActive, not recruiting

Alzheimer DiseaseActive, not recruiting

Ocular HypertensionActive, not recruiting

Androgenetic AlopeciaActive, not recruiting

DermatochalasisApproved

Graves OphthalmopathyApproved

CataractActive, not recruiting

Open-Angle GlaucomaActive, not recruiting

AlopeciaApproved

Active, not recruiting

GlaucomaApproved

Active, not recruiting

Hypotrichosis SimplexApproved

Active, not recruiting

Alzheimer DiseasePreclinical

Active, not recruiting

Ocular HypertensionApproved

Active, not recruiting

Androgenetic AlopeciaPhase 1

Active, not recruiting

DermatochalasisApproved

Approved

Graves OphthalmopathyApproved

Approved

CataractPreclinical

Active, not recruiting

Open-Angle GlaucomaApproved

Active, not recruiting

Showing 10 of 18 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zolymbus

AbbVie

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Safety and Efficacy

NCT03891446

Q3 2031

Phase 1Recruiting

Treatment

NCT03708627

Clinical

Trials by Indication[1]

Ocular Hypertension14 trials

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Completed·FForSight Vision5, Inc.·Phase 2·NCT01915940·169 enrolled

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie··NCT01646151·2,580 enrolled

24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

Completed·UUniversity of Parma·Phase 4·NCT01655758·61 enrolled

Show 11 more trials

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Completed·IInnovative Medical·Phase 4·NCT00348062

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Completed·FForSight Vision5, Inc.·Phase 1/2·NCT02742649·55 enrolled

Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT00300443·561 enrolled

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 2·NCT01291108·125 enrolled

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Completed· AbbVie logo

AbbVie··NCT01853085·1,830 enrolled

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT03850782·515 enrolled

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT04285580·37 enrolled

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02250651·528 enrolled

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02247804·594 enrolled

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02636946·144 enrolled

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02507687·240 enrolled

Glaucoma3 trials

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Completed·LLaboratoires Thea·Phase 3·NCT03825380·485 enrolled

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Unknown status·—·Phase 4·NCT04981886·115 enrolled

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Completed·LLaboratoires Thea·Phase 3·NCT05397600·684 enrolled

ESS2 trials

Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures

Completed·UUniversity of Milan·Phase 3·NCT02154217·200 enrolled

Expanded Access to Bimatoprost (Durysta)

No longer available· AbbVie logo

AbbVie··NCT05338606

Treatment2 trials

Treatment of Hypopigmented Scars With Bimatoprost

Recruiting·MMedstar Health Research Institute·Phase 2·NCT06122090·25 enrolled

Bimatoprost as a Treatment for Graves' Orbitopathy

Recruiting·JJohns Hopkins University·Phase 1·NCT03708627·3 enrolled

Hypotrichosis2 trials

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01765764·357 enrolled

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

Completed·KKenneth Beer·Phase 4·NCT01387906·20 enrolled

13 more indications

Vitiligo1 trial

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

Completed·MMedical University of South Carolina·Phase 1·NCT04738149·4 enrolled

Thyroid Eye Disease1 trial

Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)

Completed·—·Phase 4·NCT02059655·31 enrolled

Function1 trial

Stop Retinal Ganglion Cell Dysfunction Study

Terminated·UUniversity of Miami·Phase 3·NCT02390284·28 enrolled

Androgenetic Alopecia1 trial

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Terminated· AbbVie logo

AbbVie·Phase 1·NCT02676310·53 enrolled

Skin Pigmentation1 trial

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Completed·—·Phase 4·NCT00705757·89 enrolled

CLE1 trial

Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Completed·—·Phase 2·NCT02170662·33 enrolled

Migraine1 trial

Topical Bimatoprost in the Treatment of Migraine

Unknown status·MManistee Partners·Phase 2·NCT03419715·70 enrolled

Safety and Efficacy1 trial

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT03891446·455 enrolled

Growth1 trial

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

Completed·UUniversity of Miami·N/A·NCT00773136·21 enrolled

Alopecia Areata1 trial

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Completed·UUniversity of California, San Francisco·N/A·NCT00187577·14 enrolled

Systemic1 trial

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Completed·LLaboratoires Thea·Phase 1·NCT05729594·40 enrolled

Breast Cancer1 trial

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Withdrawn·JJonsson Comprehensive Cancer Center·N/A·NCT00999557

Unspecified4 trials

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Completed·FForSight Vision5, Inc.·Phase 2·NCT02143843·75 enrolled

Dose-Ranging Study of the Bimatoprost Ocular Insert

Completed·FForSight Vision5, Inc.·Phase 2·NCT02358369·156 enrolled

Bimatoprost Ocular Insert Pharmacokinetic Study

Completed·FForSight Vision5, Inc.·Phase 1·NCT02444767·11 enrolled

Show 1 more trial

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Completed·FForSight Vision5, Inc.·Phase 2·NCT02537015·81 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 16, 2001

LUMIGAN

NDA NDA021275

Dec 24, 2008

LATISSE

NDA NDA022369

Aug 31, 2010

LUMIGAN

NDA NDA022184

Mar 4, 2020

DURYSTA

NDA NDA211911

Sep 9, 2025

ZOLYMBUS

NDA NDA217307

Sources

References

[1]
ClinicalTrials.gov — 39 trial records for Bimatoprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bimatoprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bimatoprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA217307). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Zolymbus. U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Prostanoid FP Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Patent Landscape[5]

Patent Cliff

Dec 19, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9149428Dec 19, 2026

10441543Dec 19, 2026

8206737Apr 7, 2027

7851504Jun 13, 2027

7799336Apr 24, 2029

4 more patents

8629185Jul 15, 2031

9492316Oct 31, 2034

9980974Oct 31, 2034

10314780Jun 8, 2036

Zolymbus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2031

Trials by Indication[1]

Ocular Hypertension14 trials

Glaucoma3 trials

ESS2 trials

Treatment2 trials

Hypotrichosis2 trials

Vitiligo1 trial

Thyroid Eye Disease1 trial

Function1 trial

Androgenetic Alopecia1 trial

Skin Pigmentation1 trial

CLE1 trial

Migraine1 trial

Safety and Efficacy1 trial

Growth1 trial

Alopecia Areata1 trial

Systemic1 trial

Breast Cancer1 trial

Unspecified4 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News